

IMAGIN MEDICAL INC.
MANAGEMENT DISCUSSION & ANALYSIS

For the Year Ended September 30, 2018

Directors and Officers as of December 11, 2018

Directors:	Robin Atlas Chris Bleck Ken Daignault Jim Hutchens John Vacha
Officers:	President & C.E.O. – Jim Hutchens C.F.O. & Secretary – John Vacha
Contact Names:	Jim Hutchens John Vacha
Telephone Number:	833-246-2446

IMAGIN MEDICAL INC.

MANAGEMENT DISCUSSION & ANALYSIS

For the Year Ended September 30, 2018

1.1 Date of This Report

December 11, 2018

This Management's Discussion & Analysis ("MD&A") of Imagin Mining Inc. for the year ended September 30, 2018 has been prepared based on information available to us as of December 11, 2018. This discussion should be read in conjunction with the Audited Consolidated Financial Statements of the Company and notes attached thereto for the year ended September 30, 2018 included herewith, all of which are available at the SEDAR website at www.sedar.com.

This MD&A includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include product development timing, government regulatory approvals, hospital reimbursement, continued availability of capital and financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Reported currency is stated in Canadian dollars.

1.2 Overall Performance

Description of Business

Imagin Medical Inc. (formerly Expedition Mining Inc.) is incorporated in the Province of British Columbia and its previous principal business activity was the acquisition and exploration of resource properties. On February 9, 2016, the Company completed the acquisition of BSS Life Sciences Inc. ("BSS"). BSS holds the intellectual property rights to a proprietary imaging technology developed for extremely accurate visualization of cancers. In connection with the acquisition, the Company changed its name to Imagin Medical Inc. and now focuses on the research, develop and commercialization in the device/instrumentation medical technology industry.

License Agreement

By way of a Licence Agreement dated May 20, 2015, BSS was granted an exclusive, nontransferable, royalty-bearing license by Lawrence Livermore National Security, LLC (LLNS), to use LLNS's patents and intellectual property rights to manufacture and sell products and services pertaining to in-vivo imaging applications.

Under the License Agreement, BSS must:

- complete a commercial prototype by December 31, 2016 (First prototype completed);
- complete submissions for United States Food and Drug Administration (“FDA”) approval by December 31, 2017 (Not Completed and extended to Dec 31, 2019);
- achieve first commercial sales (“FCS”) in the United States within one year of achieving the FDA approval; and
- achieve gross cumulative sales revenues from the sales of licensed products of at least \$10,000,000 within the first three years of achieving FCS.

The sales requirements may be amended and/or extended at the written request of BSS to LLNS, based upon legitimate business reasons specified in reasonable detail in such written request.

BSS must pay certain fees to LLNS for the licence, being (all amounts are in US dollars):

- (i) a nonrefundable issue fee of \$100,000 payable as follows:
 - \$10,000 upon the date of execution of the Agreement (June 22, 2015; paid);
 - \$30,000 by November 22, 2015 (paid);
 - \$30,000 by January 22, 2016 (paid); and
 - \$30,000 by March 22, 2016 (paid).
- (ii) an earned royalty of 3% of net sales, subject to minimum annual royalties of:

Calendar year	Minimum annual royalty	Due date
2017	\$5,000	February 28, 2017 (paid)
2018	\$10,000	February 28, 2018 (paid)
2019	\$10,000	February 28, 2019
2020 and thereafter	\$25,000	February 28 of each year

- (iii) a nonrefundable U.S. Maintenance Patent Fee of \$45,000 to be paid as follows:
 - \$15,000 on or before February 28, 2016 (paid);
 - \$15,000 on or before February 28, 2019; and
 - \$15,000 on or before February 28, 2023

The Technology

i/Blue Imaging™ System used in conjunction with imaging agents

The Company believes it will establish a “new standard of care” for bladder cancer by addressing the limitations of current cancer detection technology used during minimally invasive surgeries. Imagin is developing advanced optic and light sensor technology that will be used in conjunction with contrast agents to dramatically improve the visualization of cancerous cells, producing superior images in less time than current methods, highlighting tumors within the bladder in high definition, including premalignant lesions

and tumor tissue along the margins for removal.

The i/Blue Imaging System is a device external to the body that attaches to an endoscope and uses both white and blue light in combination with imaging agents to cause the cancerous cells to fluoresce within an hour or less. The i/Blue Imaging System provides the option to display, in real time, the white and blue light images side-by-side or, alternatively, to blend (overlay) both images into one, producing a composite that places the cancer into context within the bladder. This advancement eliminates the surgeon's need to switch back and forth between the white and blue light images. These options make the i/Blue Imaging System more convenient and practical, improving the surgeon's ability to resect the cancer.

Producing superior image quality in less time than current systems is expected to increase the efficiency of the operating room and reduce healthcare costs by potentially enabling exams to be performed in the less-expensive physician's office.

The i/Blue's patented technology can be seamlessly adapted to most endoscopes on the market today.

Benefits of the i/Blue Imaging System

- No switching back and forth – patented *Simultaneous Acquisition of Differing Images* provides multiple display options in real time
 - White and blue light images side-by-side simultaneously
 - Composite image placing the cancer into context within the bladder
- Produces superior images in less time
- Adapts to most endoscopes on the market
- Potentially expands application to other minimally invasive procedures

Future Development

i/Vision Imaging System

The i/Vision Imaging System, the Company's next advancement, will incorporate the current features of the i/Blue Imaging System which uses the HLA contrast agent, with other fluorescing contrast agents, such as Indocyanine green (ICG). This instrument will enable expansion into multiple endoscopic procedures, cancerous or noncancerous conditions, such as laparoscopic (general and gynecology), colorectal and thoracic.

The Strategy

Imagin Medical plans to begin penetrating the estimated \$2 billion U.S. minimally invasive surgical fluorescent imaging market in 2020, developing and commercializing a portfolio of miniaturized, highly cost-effective light sources and camera systems that work with U.S. Food & Drug Administration ("FDA")-approved fluorescent agents. Simultaneously, the Company will work to partner with pharmaceutical companies that are in their final phase (Phase III) of FDA approval. The Company's products will adapt to most endoscopes on the market.

The Company's initial target market is the treatment of bladder cancer in the operating room, with expansion of bladder cancer fluorescence imaging (biopsy) to physician's offices.

Prior to commercialization of the i/Blue Imaging System in urology, the Company will begin a marketing program comprised of participating in trade shows, conducting focus groups, developing physician champions and establishing Centers of Excellence. The marketing program will also continue to build on management's current relationships with key successful independent sales representatives who currently call on hospitals and urologists.

When the i/Blue Imaging System is established in urology, Imagin will focus on expanding the product platform of miniaturized cameras and light sources from bladder cancer to abdominal, colorectal, thoracic and other procedures.

Imagin plans to build relationships with complementary products to expand our portfolio. Because the i/Blue technology is adaptable to most endoscopes currently on the market, the Company will be of strategic interest existing dominant endoscope manufacturers.

Intellectual Property

The Company, through its wholly owned subsidiary (BSS Life Sciences) has secured an exclusive license from Lawrence Livermore National Security, LLC (LLNS) to commercialize the technology invented by Dr. Stavros Demos. This license agreement includes three issued patents and one pending patent application on technology related to exclusive spectroscopic imaging for cancer and other medical applications. These include:

1. Issued U.S. Patent 7,149,567 - Near-Infrared Spectroscopic Tissue Imaging for Medical Applications
2. Issued U.S. Patent 7,257,437 - Autofluorescence Detection and Imaging of Bladder Cancer Realized Through a Cystoscope.
3. Issued U.S. Patent 8,285,015 - Simultaneous Acquisition of Differing Image Types
4. Pending U.S. Patent Application No. 13/601,918 - Simultaneous Acquisition of Differing Image Images

The Company is also planning to file additional patent applications in the future.

Product Development Plan and Timing

In 2017 the Company's development team successfully retrofitted an original prototype making significant improvements to its internal components, image processing and display software, integrating state-of-the art, high resolution cameras and patented, image-blending technology with other proprietary elements. Using the retrofitted prototype, a

Research Study was conducted at the University of Rochester Medical Center in Rochester, NY, under the guidance of Dr. Edward Messing, Chair of Urology at the Medical Center and a renowned expert in the diagnosis and treatment of urological cancers.

Feedback from the 10-subject study was valuable and has been incorporated into the redesign of the system for manufacturability and commercialization by Optel, Inc., Imagin's design firm. Optel's extensive experience with integrating optics, mechanics, electronics and software into user friendly, cost effective products has been key to reaching the Company's design goals of providing better images in less time with software that allows multiple images to be displayed simultaneously.

Optel has completed the Proof of Concept Phase of this redesigned model, validating the performance of the two critical optical modules of the i/Blue Imaging System: light source and imaging modules. Functional units for testing will be available in Q1 2019. The final phase of a Verified Unit for manufacturing is expected to be completed in late Q2 2019. The Company believes that the miniaturization, imaging quality and cost reduction goals for the i/Blue Imaging System will be achieved as Optel further optimizes the system and works toward commercialization. The product will be highly manufacturable and cost effective, with a modular design that will become a basic platform for Imagin's current and future imaging systems and applications.

Imagin intends to meet with the FDA during the 1Q 2019 to discuss the regulatory path and potential clinical study. The Company is confident that the studies needed to establish the product's safe and effective use with approved imaging agents would be comparative studies, using our own and currently existing technologies, rather than requiring Imagin to re-establish that the already approved drugs are effective.

Imagin Medical will ensure that the i/Blue Imaging System will be in compliance with the requirements of the FDA, Good Manufacturing Practices (GMP), European medical device standard ISO 13485, and other international compliance requirements.

Depending on the FDA device classification, schedule and marketing clearance, the Company is planning to initiate the commercialization of the i/Blue Imaging Systems during calendar year 2020 and believes it will achieve rapid revenue growth.

Highlights from Oct 1, 2017 up to the date of this report

The Company announced the following:

- closed a non-brokered Private Placement with the issuance of 20,000,000 units priced at \$0.05 per unit for gross proceeds of \$1,000,000. Each Unit of this Private Placement will consist of one common share of the Company and one common share purchase warrant ("Warrant"), each warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.10 within the 12 months.

- closed a \$120,000 financing to raise funds to be used for the Company's communications program. The funds raised pursuant to the Financing will be specifically targeted for a communications and marketing program, allowing the Company to continue to maintain its existing cash for product development and commercialization. The Financing will consist of 800,000 units (the "Units") at a price of \$0.15 per Unit, each Unit to be comprised of one common share and one half of one common share purchase warrant (the "Warrants"). Each whole Warrant will be exercisable into one common share in the equity of the Company (the "Warrant Shares") at an exercise price of \$0.25 per Warrant Share. The Warrants expire one year from date of issuance.
- announced that Roger J. Buckley, M.D., Chief of Urology at North York General Hospital in Toronto, Vice President of the International Bladder Cancer Group (IBCG), and a member of Imagin's Scientific Advisory Board, attended the 37th Congress of the Society of International Urology held October 19 through 22 in Lisbon, Portugal.
- confirmed that experts in the field of urology concur that one reason for the high recurrence rate after transurethral resection (TUR), is that some cancer not seen was left behind by the surgeon. The Company's i/Blue Imaging System is expected to reduce the time for physicians to visualize the cancer to ten minutes.
- announced that Optel, Inc., the Company's optical product-design firm, will begin the redesign of the i/Blue Imaging System prototype for manufacturability and commercialization. The redesign will be concurrent with the first in-human research study using the i/Blue prototype that is anticipated to begin shortly at the University of Rochester Medical Center.
- announced the first in-human Research Study using the i/Blue Imaging System is open for enrollment and recruitment has begun at the University of Rochester Medical Center.
- announced the grant of an aggregate of 2 million stock options to certain directors, officers and consultants at an exercise price of \$0.25, exercisable for a period of five years.
- announced the approval of a bonus payable of 5 million shares to the President and CEO for his part in the Company's recent success in advancing its technology with the University of Rochester and raising much needed working capital funds.
- announced that the Company has received more than \$1,000,000 through the exercising of warrants by long-term investors.
- announced that it hired John Vacha as the Company's new CFO.
- announced that a number of clinical procedures have been performed and technical progress continues as this investigative research program focuses on the rapid interoperative identification of bladder cancer.
- announced the closing of a non-brokered private placement for \$200,000 through the issuance of 625,000 shares at \$0.32 for the Company's ongoing communications and marketing program.
- announced the closing of a non-brokered private placement for \$240,000 through the issuance of 888,889 shares at \$0.27 for the Company's ongoing communications and marketing program.

- announced that further to its press release of April 3, 2018, the Company closed its non-brokered Private Placement (Tranche 1 and 2) through the issuance of 17,919,820 units (the “Units”) priced at \$0.22 per Unit for gross proceeds of \$3,942,361. Each Unit of this Private Placement will consist of one common share of the Company and one common share purchase warrant (“Warrant”), each Warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.38 for 24 months from the date of issue.
- Total finders’ fees will be paid in the form of cash in the amount of \$223,267 and 1,117,110 finders’ warrants (exercisable at \$0.38 per share for 24 months). All securities issued will be subject to a four-month hold period.
- announced positive progress in the I/Blue Imagin System Research Study.
- announced that it has engaged the services of Kilmer Lucas Inc. for cross-border investor relations.
- announced further details regarding the engagement of Kilmer Lucas Inc.
- announced that its common shares were approved for uplisting from the Pink Open Market to the OTCQB Venture Market, effective June 28, 2018.
- announced favorable results from the I/Blue Imagin System Research Study.
- granted 500,000 incentive stock options with an exercise price of \$0.16 to certain technical consultants. Options are fully vested and expire July 25, 2023.
- announced the appointment of Chris Bleck to the Board of directors and the resignation of Steve Chan.
- announced the exercise of 9,533,540 previously issued share purchase warrants for total proceeds of \$954,854.
- at the date of this report, the Company currently has 139,060,278 issued and outstanding Shares; 1,100,000 Acquisition Warrants; 19,799,675 Finance Warrants; 1,214,070 finders’ warrants; 387,032 debt conversion warrants; and 10,100,000 incentive stock options.

1.3 **Selected Annual Information**

The highlights of financial data for the Company for the two most recently completed financial years are as follows:

	<u>Imagin</u> <u>Medical Inc.</u> <u>Sept. 30, 2018</u>	<u>Imagin</u> <u>Medical Inc.</u> <u>Sept. 30, 2017</u>
(a) Loss before other items		
(i) Total loss	\$4,988,339	\$1,377,537
(ii) Loss per share – basic	\$0.05	\$0.03
(iii) Loss per share – diluted	\$0.05	\$0.03
(b) Net loss		
(i) Total loss	\$7,958,086	\$1,542,102
(ii) Loss per share – basic	\$0.07	\$0.03
(iii) Loss per share – diluted	\$0.07	\$0.03
(c) Total assets	\$6,171,702	\$389,644

1.4 **Results of Operations**

Discussion of Operations and Financial Condition

The following should be read in conjunction with the condensed interim consolidated financial statements for the year ended September 30, 2018 and notes attached hereto.

During the year ended September 30, 2018, the Company reported a net loss of \$7,958,086 (\$1,542,102 – September 30, 2017). The Company incurred the following major expenditures:

1. Consulting fees – Total \$1,768,998 (Increased by \$1,438,486)
2. Marketing and Investor Relations – The Company engaged numerous consultants to provide services primarily related to raising capital and public relations, specifically, internet marketing, research reports, news and press releases and their distribution. The Company continues with its ongoing communications and marketing programs to efficiently increase awareness of the progress of the Company, allowing the Company to continue to maintain its existing cash for product development and commercialization.
3. Corporate & administration fees – Total \$90,125 (Increased by \$31,663)
 - The increase is mainly related to the numerous private placements the Company closed during the period.
4. Legal & accounting – Total \$358,619 (Increased by \$232,140)
 - During the second quarter, the Company hired John Vacha as the new Chief Financial Officer. Jorge Avelino, the former Chief Financial Officer continues to work with the Company assisting with the regulatory and accounting functions.
5. Management fees – Total \$1,642,857 (Increased by \$1,300,574)
 - During the second quarter, the Company paid the President a bonus of 5,000,000 shares as per corporate resolution dated August 15, 2017. The Company recorded the transaction at a price of \$0.235 per share, which was the closing price of the stock at the date of issuance.
6. Product Development – Total \$806,849 (Increased by \$479,492)
 - The increase is primarily related to the work performed by outsourced quality, regulatory, design and engineering consultants as well as fees related to the 1st in-human Research Study at the University of Rochester Medical Center and Optel Inc.
7. Stock-based compensation – Total \$2,962,098 (Increased by \$2,803,077)
 - During fiscal 2018, the Company granted 11,300,000 incentive stock options with prices ranging from \$0.16 to \$0.40 (September 30, 2017 – 2,650,000 with prices ranging from \$0.06 to \$0.15).

The Company also reported receivables and prepaids for a total amount of \$211,141 (September 30, 2017 - \$776). The amount is broken down as follows:

	30-September-18	30-Sep-17
GST Receivable	\$ 7,398	492
Interest Receivable	19,560	284
Prepaid expenses **	174,183	-
Trust account	10,000	
	\$ 211,141	776

** The Company was billed in advance for services ranging from 6 months to a year with respect to services primarily related to raising capital and public relations, specifically, internet marketing, digital marketing, research reports, news and press releases and their distribution. These amounts are recorded as prepaid and expensed on a monthly basis.

Shareholders Communication and Travel

The Company reported shareholder communication and travel expenses totaling \$91,925 and broken down as follows:

	30-September-18	30-September-17
Communication & information	\$ 21,273	\$ 9,661
Conferences	7,303	10,140
Press releases	17,718	4,000
Telephone & website	13,275	5,496
Travel & entertainment	32,356	19,752
	\$ 91,925	\$ 49,049

Summary of Quarterly Results

The following is a summary of the Company's financial results for the eight most recently completed quarters:

	<u>Q4 30-Sep-18</u>	<u>Q3 30-Jun-18</u>	<u>Q2 31-Mar-18</u>	<u>Q1 31-Dec-17</u>
	IFRS	IFRS	IFRS	IFRS
Net loss	(2,217,112)	(1,751,665)	(2,718,811)	(1,270,498)
Per Share	(2.0)	(1.5)	(2.5)	(1.5)
	<u>Q4 30-Sep-17</u>	<u>Q3 30-Jun-17</u>	<u>Q2 31-Mar-17</u>	<u>Q1 31-Dec-16</u>
	IFRS	IFRS	IFRS	IFRS
Net loss	(373,798)	(298,242)	(381,507)	(488,555)
Per Share	(0.01)	(0.005)	(0.005)	(0.01)

On February 9, 2016, the Company completed the acquisition of BSS Life Sciences ("BSS"). In connection with the closing, the Company issued 26,500,000 common shares to the shareholders of BSS (see note 10). As a result of the exchange, the transaction resulted in a reverse asset acquisition. Accordingly, BSS will be considered the continuing entity for accounting and financial reporting purposes and the Company, the continuing public company, being the corporation acquired. Therefore, all financial statements prior to the acquisition date are not presented in this report.

Discussion

Year ended September 30, 2018:

For the year ended September 30, 2018, please refer to Section 1.4 Results of Operations.

1.5 Liquidity

The Company has no current operating income or cash flow. In management's view, given the nature of the Company's operations, the most relevant financial information relates primarily to current liquidity, solvency and planned expenditures. The Company's financial success will be dependent on continuing to raise operating capital and successful clinical trials that validate the company's technology and such activities may take time to complete and the amount of resulting income is difficult to determine. The Company completed two non-brokered private placements through the issuance of 20,000,000 units for gross proceeds of \$1,000,000 and 17,919,820 units for gross proceeds of \$3,942,360. Both private placements consisted of one common share of the Company and one warrant ("Warrant"), each Warrant entitling the holder thereof to acquire one additional common share of the Company at a price of \$0.10 within 12 months and \$0.38 for 24 months. In addition, the following options and warrants were exercised.

In addition, the following options and warrants were exercised during the period ended September 30, 2018:

- i. issued 31,539,580 common shares from the exercise of acquisition warrants, finance warrants and finders' warrants, with prices ranging from \$0.12 to \$0.35 for total proceeds of \$4,227,414.
- ii. issued 5,600,000 common shares from the exercise of stock options, with prices ranging from \$0.06 to \$0.26 for total proceeds of \$ 952,000.
- iii. Issued 1,200,520 common shares \$0.12 from the conversion of convertible debt for total proceeds of \$108,047.

As at September 30, 2018, the Company had \$5,818,840 in cash, \$5,750 in security deposits and \$211,140 in accounts receivable and prepaid expenses. The Company currently has no revenue being generated from its i/Blue system for the early detection of cancer. The Company believes that after the clinical studies are completed and the final FDA clearance, sales will begin in 2020.

The Company's historical capital needs have been met by equity subscriptions. On September 30, 2018, the Company had working capital of \$5,856,202 (September 30, 2017 – working capital deficiency of \$648,351).

Cash and cash equivalents

	30-Sep-18	30-Sep-17
Cash deposits	\$ 2,318,840	\$ 245,921
Guaranteed investment certificate	3,500,000	
Total cash and cash equivalents	\$ 5,818,840	\$ 245,921

As at September 30, 2018, the Company held US\$76,100 (included in the above).

Credit Risk

Credit risk arises from cash held with banks and financial institutions. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The Company's cash is held with a Canadian bank.

Currency Risk

Currency risk is the risk to the Company's earnings that arises from fluctuations of foreign exchange rates and the degree of volatility of these rates. The Company faces certain foreign exchange risks related to expenses incurred in U.S. dollars, a currency which may appreciate against the Canadian dollar, the Company's reporting currency. Additionally, net working capital balances denominated in non-reporting currencies are also subject to fluctuations in value. The Company mitigates these threats by limiting its exposure to such balances where their expenditure in the same non-reporting currency is not imminent.

Commitments

The Company has certain commitments related to the license agreement with Lawrence Livermore National Security. Please refer to Sections 1.2 Overall Performance – License Agreement.

1.6 Capital Resources

The Company's capital resources is fixed assets (computers & office equipment) with a book value of \$1,403 (\$2,005 – September 30, 2017).

1.7 Off Balance Sheet Arrangements

There are no off-balance sheet arrangements to which the Company is committed.

1.8 Fourth Quarter

The fourth quarter result does not differ significantly from other quarters.

1.9 Transactions with Related Parties

During the year ended September 30, 2018, the Company paid or accrued \$1,918,415 (September 30, 2017 - \$432,283) to directors and officers or companies controlled by directors and officers of the Company, for management, accounting, and directors fees incurred by the Company.

		30-Sep-18	30-Sep-17
Management fees	\$	1,642,857	342,283
Accounting fees		212,401	72,000
Consulting fees		35,012	0
Directors fees		28,145	18,000
Total	\$	1,918,415	432,283

During the year ended September 30, 2018, the Company granted a total of 4,200,000 incentive stock options to the directors and officers at exercise prices ranging from \$0.18 to \$0.40, vesting immediately and expiring within 5 years. The fair value of the options granted ranged from \$0.1743 to \$0.3954 for total stock-based compensation of \$1,191,910.

Included in accounts payable are fees and expenses due to directors and officers in the amount of \$14,776 (September 30, 2017 - \$614,160), which are non-interest bearing, unsecured, and payable on demand. Fair value cannot be reliably determined.

1.10 Proposed Transactions

N/A

1.11 Critical Accounting Estimates

In preparing financial statements, management has to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Based on historical experience, current conditions and expert advice, management makes assumptions that are believed to be reasonable under the circumstances. These estimates and assumptions form the basis for judgments about the carrying value of assets and liabilities and reported amounts for revenues and expenses. Different assumptions would result in different estimates and actual results may differ from results based on these estimates. These estimates and assumptions are also affected by management's application of accounting policies. Critical accounting estimates are those that affect the consolidated financial statements materially and involve a significant level of judgment by management.

1.12 Financial and Other Instruments

The carrying value of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and due from (to) related parties approximate their fair values due to the short maturity of those instruments.

1.13 Other

Disclosure of Outstanding Share Capital: December 11, 2018

	<u>Number</u>
Common Shares	<u>139,060,278</u>

Disclosure of Outstanding Stock Options: December 11, 2018

	<u>Number</u>
Incentive Stock Options	<u>10,100,000</u>

Disclosure of Outstanding Share Purchase Warrants: December 11, 2018

	<u>Number</u>
Warrants	<u>20,523,962</u>
Fully diluted	<u>169,684,240</u>

Disclosure Controls and Procedures

It should be noted that pursuant to Multilateral Instrument 52-511 (adopted by the British Columbia Securities Commission on November 23, 2007), that the officers of the Company are no longer required to certify the effectiveness of disclosure controls and procedures used by the Company, as was required in previous filings under National Instrument 52-109. Accordingly, the new forms of certificate to be signed by the Company's Chief Executive Officer and Chief Financial Officer contain the following Note to Reader:

In contrast to the certificate required under National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of:

- (i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- (ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

The issuer's certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate.

Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost-effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of and annual filings and other reports provided under securities legislation.

Subsequent Events

Subsequent to the year ended September 30, 2018, the following occurred:

- 5,133,340 finance warrants with an exercise price of \$0.10 were exercised for gross proceeds of \$513,334;
- 8,000 finder's warrants with an exercise price of \$0.10 were exercised for gross proceed of \$800;
- 62,500 finance warrants with and exercise price of \$0.16 were exercised for gross proceeds of \$10,000;
- 2,000 finder's warrants with an exercise price of \$0.16 were exercised for gross proceeds of \$320;
- 616,760 finance warrants with an exercise price of \$0.10 expired on October 16, 2018
- 475,000 finance warrants with an exercise price of \$0.16 expired on October 18, 2018;

- 82,500 finders' warrants with an exercise price of \$0.16 expired on October 18, 2018;
- 400,000 finance warrants with an exercise of price of \$0.25 expired on November 1, 2018;
- 1,879,855 finance warrants with an exercise price of \$0.16 expired on December 9, 2018;
- 96,960 finders' warrants with an exercise price of \$0.16 expired on December 9, 2018.

Additional information relating to the company is on SEDAR at www.sedar.com.